Latest News on OMCL

Financial News Based On Company


Advertisement
Advertisement

Omnicell, Inc. (OMCL) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_4175_QuantitativeReport_1794960000000
Argus has lowered its target price for Omnicell Inc. (OMCL) to $32.00, citing the company's role in providing automation and business analytics software for healthcare providers. The company is focused on transforming pharmacy and nursing care delivery. The current stock price for OMCL is $34.66.

Form 144 OMNICELL For: 16 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-omnicell-for-16-november-93CH-4961945
This article announces the Form 144 filing for Omnicell (OMCL) on November 16, 2026. Form 144 is a notice of the intent to sell restricted securities. The article provides minimal details beyond the filing announcement and a slight increase in OMCL's stock price.

Omnicell (OMCL) officer proposes selling 3,083 shares after restricted-stock vesting.

https://www.stocktitan.net/sec-filings/OMCL/144-omnicell-inc-sec-filing-2d9e40af5a80.html
Omnicell officer Nnamdi T. Njoku has proposed selling 3,083 common shares, valued at $107,905.00, with an approximate sale date of November 16, 2026. These shares were acquired through restricted-stock vesting on November 15, 2026, under a Rule 10b5-1 plan adopted in February 2026. This notice also reports a prior sale of 3,083 shares on August 17, 2026, for gross proceeds of $113,608.55.

Clients own the 952,749 Omnicell (OMCL) shares reported by Wellington.

https://www.stocktitan.net/sec-filings/OMCL/schedule-13g-a-omnicell-inc-amended-passive-investment-disclosure-aaaab3736f9d.html
Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP have filed an amended beneficial-ownership report for Omnicell, Inc. (OMCL). Each entity reported beneficial ownership of 952,749 shares, representing 2.09% of the class, with shared voting power over 827,035 shares and shared dispositive power over 952,749 shares. The shares are owned of record by clients of Wellington Investment Advisers, who retain the right to dividends and sale proceeds, with no single client holding rights over more than 5% of the class.

There May Be Underlying Issues With The Quality Of Omnicell's (NASDAQ:OMCL) Earnings

https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/there-may-be-underlying-issues-with-the-quality-of-omnicells
Omnicell's recent strong earnings haven't significantly boosted its stock, possibly due to shareholders noting a concerning boost from US$7.5m in unusual items. These one-off items suggest that the reported statutory profits might not accurately reflect the company's underlying earning power. While EPS growth was high over the last year, future profits might be weaker if these unusual items do not recur.
Advertisement

Wondering Why Omnicell Fell? Here's What Bears Saw

https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/wondering-why-omnicell-fell-heres-what-bears-saw
Omnicell's stock (NasdaqGS:OMCL) has fallen 20.5% year-to-date in 2026, driven by mixed Q3 results that showed revenue decline but improved net income. While bullish arguments focused on SaaS growth and higher profit margins, bearish concerns about government cost controls and cybersecurity spending appear to have been partially validated. Future performance hinges on the success of its Titan XT and OmniSphere refreshes in converting pipeline into durable, higher-margin recurring revenue.

Is Omnicell (OMCL) A Bargain As Higher Guidance Resets Its Valuation?

https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/is-omnicell-omcl-a-bargain-as-higher-guidance-resets-its-val
Omnicell (OMCL) recently updated its guidance, projecting higher full-year revenue and stronger earnings per share, particularly focusing on recurring software and services. Despite a choppy share price performance year-to-date, the company now trades at a discount to analyst targets and intrinsic value estimates, valued at $57.43 per share by one narrative. Investors are evaluating whether Omnicell's transition to SaaS and the OmniSphere platform can support these positive assumptions, especially given its P/E ratio is currently higher than both peers and the broader US Medical Equipment industry.

Will Higher Profit And New Guidance Change Omnicell Stock's Narrative

https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/will-higher-profit-and-new-guidance-change-omnicell-stocks-n
Omnicell reported third-quarter 2026 revenue of US$307.85 million and net income of US$11.04 million, raising its full-year revenue guidance to US$1.225 billion - US$1.231 billion. The improved profitability, despite modest revenue growth, highlights the company's focus on cost discipline and efficiency. This performance shapes the investment narrative more towards margin quality than rapid sales acceleration, with analysts projecting continued earnings growth through 2029.

Omnicell, Inc. (OMCL) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/OMCL/seasonality/
The article provides a seasonal returns chart for Omnicell, Inc. (OMCL) on Yahoo Finance. It displays the average monthly price return for OMCL from 2016 to 2026, alongside current stock data and various financial analysis tools. The stock closed at $37.34 on November 6, down 1.81%.

Omnicell, Inc. (OMCL) Seasonal returns chart

https://sg.finance.yahoo.com/quote/OMCL/seasonality/
This article from Yahoo Finance provides a seasonal returns chart for Omnicell, Inc. (OMCL). It displays the average monthly price return for the company's stock between 2016 and 2026. The article includes current stock prices and market performance data for various global indices and cryptocurrencies.
Advertisement

Revenue slips to $307.9M at Omnicell (OMCL), but quarterly net income rises.

https://www.stocktitan.net/sec-filings/OMCL/10-q-omnicell-inc-quarterly-earnings-report-87ff05659dfa.html
Omnicell, Inc. (OMCL) reported a slight revenue decrease to $307.9 million in Q3 2026 from $310.6 million a year prior, but saw its net income double to $11.0 million from $5.5 million. For the first nine months of 2026, revenue increased to $929.9 million from $870.9 million, with net income surging to $46.7 million compared to $4.1 million in the same period of 2025. The company's cash provided by operating activities also significantly increased to $155.9 million.

Omnicell (OMCL) Stock Looks Cheap Based On Cash Flow Value

https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/omnicell-omcl-stock-looks-cheap-based-on-cash-flow-value
Omnicell (OMCL) stock appears undervalued based on a Discounted Cash Flow (DCF) analysis, despite a significant 79.7% fall over the past five years. The DCF model, which projects future free cash flow, suggests the company's intrinsic value is substantially higher than its current share price of US$36.41. This valuation indicates the market may be overly cautious about the timing and durability of Omnicell's cash flows, which are expected to grow in the coming decade.

Omnicell, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:OMCL) 2026-11-02

https://seekingalpha.com/article/4961193-omnicell-inc-2026-q3-results-earnings-call-presentation?source=generic_rss
Omnicell, Inc. (NASDAQ:OMCL) published its Q3 2026 earnings call presentation, reporting an EPS of $0.58, which beat estimates by $0.16. The company's revenue for the quarter was $307.85M, a slight decrease of 0.89% year-over-year, but still beat expectations by $3.37M. This presentation accompanies their earnings call on November 2, 2026.

BTIG Maintains Omnicell(OMCL.US) With Hold Rating

https://www.moomoo.com/news/post/1002995043/btig-maintains-omnicell-omclus-with-hold-rating
BTIG has maintained its Hold rating on Omnicell (OMCL.US). The article does not provide further details on the reasons for this rating.

Omnicell, Inc. Stock 12‑Month Price Target Cut to $57.14, Implies 59% Upside

https://www.tradingview.com/news/tradingview:34113f858f3b7:0-omnicell-inc-stock-12-month-price-target-cut-to-57-14-implies-59-upside/
Omnicell, Inc. (OMCL) has seen its average 12-month price target adjusted to $57.14, down from $57.86, according to estimates from 7 analysts. This new target suggests a potential upside of approximately 59% based on the Oct. 28 closing price. The consensus analyst rating for Omnicell remains "Buy," with 7 Buys, 1 Hold, and 0 Sells from 8 covering analysts.
Advertisement

Omnicell (NASDAQ:OMCL) exceeds Q3 2026 expectations but quarterly revenue guidance misses expectations

https://www.tradingview.com/news/stockstory:64bd89fa4094b:0-omnicell-nasdaq-omcl-exceeds-q3-2026-expectations-but-quarterly-revenue-guidance-misses-expectations/
Omnicell (NASDAQ:OMCL) reported better-than-expected Q3 2026 revenue and adjusted EPS, with revenue flat year-on-year at $307.9 million and adjusted EPS significantly beating estimates at $0.58. However, the company's Q4 2026 revenue guidance of $298 million fell short of analysts' consensus. Despite the mixed outlook, shares rose 2.8% immediately after the results.

Omnicell Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/10/62696437/omnicell-q3-2026-earnings-call-transcript
Omnicell Inc. reported strong Q3 2026 financial results, exceeding revenue and non-GAAP EBITDA guidance, driven by effective execution and a strategic focus on autonomous medication management. The company is advancing its Omnisphere cloud-native platform and Titan XT hardware, with a growing pipeline supported by leasing programs, while navigating a measured capital environment among health systems. Management emphasized reliability, service, and innovation as key differentiators, with Omnisphere's subscription model gaining favorable customer reception.

Omnicell stock surges 10% on third quarter earnings beat

https://www.investing.com/news/earnings/omnicell-stock-surges-10-on-third-quarter-earnings-beat-93CH-4982643
Omnicell, Inc. reported adjusted earnings per share of $0.58, exceeding analyst estimates of $0.42, and revenue of $307.85 million, above the $304.43 million estimate. The company's shares jumped nearly 10% in pre-market trading following the announcement. Omnicell also provided optimistic adjusted EPS guidance for the fourth quarter and full year 2026, though its fourth-quarter revenue guidance fell slightly short of consensus.

Omnicell earnings on deck as analysts eye margin sustainability

https://www.investing.com/news/earnings/omnicell-earnings-on-deck-as-analysts-eye-margin-sustainability-93CH-4979579
Omnicell Inc. is set to report third-quarter earnings, with analysts focusing on the sustainability of its profitability after a stronger-than-expected Q2. The company faces scrutiny over potential sequential and year-over-year declines in earnings and revenue amidst increasing competition and a shift towards AI-driven medication management. Despite near-term challenges, analysts maintain a "Strong Buy" rating with significant upside potential.

Omnicell earnings: what to look for from OMCL

https://markets.financialcontent.com/stocks/article/stockstory-2026-10-28-omnicell-earnings-what-to-look-for-from-omcl
Omnicell (NASDAQ: OMCL) is set to report earnings this Thursday before market hours. The market anticipates a 1.5% year-on-year revenue decline, contrasting with last year's 10% increase. Despite a mixed previous quarter with an EPS beat but missed EBITDA guidance, analysts have generally maintained their estimates, and the company rarely misses Wall Street's revenue forecasts.
Advertisement

Omnicell, Inc. Estimates – NASDAQ:OMCL

https://www.tradingview.com/symbols/NASDAQ-OMCL/financials-estimates/
This article provides an overview of Omnicell, Inc. (NASDAQ: OMCL) financial estimates available on TradingView. It directs users to explore reported financial data and analyst estimates across various statements, including income, balance sheet, cash flow, and valuation metrics. The platform allows for comparison of actual results with average, high, and low estimates, and visualization of trends over time.

Omnicell [NASDAQ:OMCL] | Top Medication Management Solutions 2026

https://www.healthcaretechoutlook.com/omnicell-2026
Omnicell has been recognized as a top medication management and pharmacy management solutions provider for 2026 by Healthcare Tech Outlook Magazine. The company focuses on connecting every step of medication management, from central pharmacy robotics to automated dispensing systems, to improve medication availability and efficiency in hospitals. Their approach integrates physical movement of medications with information management, aiming to make medication availability more predictable and reduce operational complexities.

Earnings Preview: Omnicell to Report Financial Results Pre-market on October 29

https://www.moomoo.com/news/post/1002243119/earnings-preview-omnicell-to-report-financial-results-pre-market-on
This article provides an earnings preview for Omnicell (OMCL), stating the company is scheduled to release its financial results pre-market on October 29. It will also host a conference call on the same day to discuss these results.

Omnicell sets October 29 results. Omnicell stock sits 26.90 percent below target

https://www.ad-hoc-news.de/boerse/news/nebenwerte/omnicell-sets-october-29-results-omnicell-stock-sits-26-90-percent-below-target/70377171
Omnicell is scheduled to release its third-quarter 2026 results on October 29, 2026, before the market opens, followed by a conference call. The company's stock was trading at EUR 32.50 at Lang & Schwarz and USD 36.55 on Nasdaq on October 20, 2026, which is below the Wells Fargo target of USD 50.00. Analysts expect third-quarter revenue of USD 304.45 million and earnings of USD 0.4175 per share, following a strong Q2 2026 performance with revenue of USD 312.21 million.

Wells Fargo keeps USD 50.00 target for Omnicell stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/wells-fargo-keeps-usd-50-00-target-for-omnicell-stock/70348935
Wells Fargo has maintained its USD 50.00 price target and Buy rating for Omnicell (OMCL), indicating a potential 41.28% upside from its last traded price of USD 35.39. This comes as Omnicell reported Q2 2026 revenue of USD 312.21 million, up 7.40% year-over-year, and prepares to release its Q3 2026 results on October 29, 2026. The company, which provides medication-management technology, has a market capitalization of USD 1.6 billion and a trailing P/E ratio of 41.89.
Advertisement

Omnicell, Inc. (OMCL) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_4175_QuantitativeReport_1791936000000
Argus has raised its target price for Omnicell Inc. (OMCL) to $35.00, noting the company's role in providing automation and business analytics software for healthcare providers. Omnicell is focused on transforming the pharmacy and nursing care delivery model. The current stock price for OMCL is $35.39.

Did Omnicell's Fall Catch You Out? What Investors Missed

https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/did-omnicells-fall-catch-you-out-what-investors-missed
Omnicell's stock (NASDAQGS:OMCL) has fallen by 21.6% since the start of the year despite Q2 2026 results showing increased revenue and net margin, driven by its shift towards cloud software and automation. The company's transition to a tech-enabled, platform-based business with growing recurring revenues supports a narrative of stronger future earnings, but execution risks and cost pressures remain. Investors are left to weigh whether the current price represents an opportunity based on confidence in its software-heavy model or a warning given ongoing headwinds.

Did Omnicell's Fall Catch You Out? What Investors Missed

https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/did-omnicells-fall-catch-you-out-what-investors-missed/amp
This article analyzes Omnicell's recent stock performance, which saw a 21.6% loss despite rising quarterly revenue and an increased net margin, driven by its Autonomous Pharmacy and cloud platform initiatives. It contrasts bullish and bearish narratives for the company, highlighting the importance of margin quality in evaluating its shift to a software-heavy model. The piece suggests that for the stock's fall to be an opportunity rather than a warning, investors need to believe that recurring cloud and services revenue can overcome current headwinds and lead to sustained profitability.

Omnicell, Inc. (OMCL) stock price, news, quote and history

https://au.finance.yahoo.com/quote/OMCL/
This article provides a detailed financial overview of Omnicell, Inc. (OMCL), including its current stock price, market performance, and key financial metrics. It also offers an overview of the company's healthcare technology solutions and recent analyst ratings. The data shows OMCL's performance against the S&P 500 across various periods.

Is This the Right Time to Retain Omnicell Stock in Your Portfolio?

https://finance.yahoo.com/healthcare/articles/time-retain-omnicell-stock-portfolio-122300631.html
Omnicell's autonomous pharmacy strategy and cost discipline have led to an improved outlook for 2026 EBITDA and earnings, with strong customer engagement for its products. While the company is focused on market expansion, recurring revenue growth, and advancing its OmniSphere platform, it faces challenges from rising memory costs and potentially slower adoption of its Titan XT due to a younger installed base. Despite these headwinds, Omnicell has consistently surpassed earnings estimates and its stock has outperformed the industry.
Advertisement

Is This the Right Time to Retain Omnicell Stock in Your Portfolio?

https://www.tradingview.com/news/zacks:b40cae455094b:0-is-this-the-right-time-to-retain-omnicell-stock-in-your-portfolio/
Omnicell (OMCL) is leveraging its autonomous pharmacy strategy to improve efficiency and reduce medication errors, with strong engagement for its Titan XT and OmniSphere products. The company raised its 2026 EBITDA and earnings outlook due to cost discipline and operational efficiency. Despite potential challenges from rising memory costs and lengthy customer approval processes for Titan XT, Omnicell's strategic priorities aim for broader product adoption, recurring revenue growth, and advancing its OmniSphere platform.

The Technical Signals Behind (OMCL) That Institutions Follow

https://news.stocktradersdaily.com/news_release/149/The_Technical_Signals_Behind_OMCL_That_Institutions_Follow_101326120002_1791907202.html
This article from Stock Traders Daily analyzes Omnicell Inc. (OMCL) using AI models to identify technical signals and institutional trading strategies. Key findings include a potential for long-term strong sentiment, a mid-channel oscillation pattern, and a high risk-reward short setup. The analysis provides specific entry zones, targets, and stop losses for position, momentum breakout, and risk hedging strategies across different time horizons.

Learn Why The Bull Case For Omnicell Stock Could Change Following Weak EBITDA Guidance

https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/learn-why-the-bull-case-for-omnicell-stock-could-change-foll/amp
Omnicell's recent financial report showed revenue slightly above expectations but EBITDA guidance below forecasts, indicating profitability challenges despite solid sales. This suggests rising costs and pricing pressures could hinder the company's ability to translate top-line growth into stronger earnings. The article explores how this contrast between revenue and EBITDA guidance might reshape the investment narrative for Omnicell, focusing on the importance of its shift towards higher-margin recurring software and services like OmniSphere.

Omnicell, Inc. (OMCL) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/OMCL/
This page provides a comprehensive overview of Omnicell, Inc. (OMCL) stock, including its current price, news, detailed quotes, and historical data. It features real-time price updates, performance charts over various periods, key financial metrics, and company information. The article also includes recent news, performance overviews against benchmarks like the S&P 500, earnings trends, analyst insights with price targets and recommendations, and detailed financial statistics.

Learn Why The Bull Case For Omnicell Stock Could Change Following Weak EBITDA Guidance

https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/learn-why-the-bull-case-for-omnicell-stock-could-change-foll
Omnicell's recent quarterly report showed revenue slightly above expectations but weaker EBITDA guidance, signaling potential profitability pressures despite solid sales. The company's investment narrative hinges on its shift towards higher-margin recurring software and services like OmniSphere, which analysts project will drive significant earnings growth and margin expansion by 2029. However, the softer EBITDA outlook reinforces risks related to cost inflation and pricing pressures, challenging the company's ability to translate top-line growth into stronger operating earnings.
Advertisement

Omnicell, Inc. (OMCL) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/OMCL/
This article provides an overview of Omnicell, Inc. (OMCL) stock, including its current price, key statistics, and historical performance. It details the company's healthcare technology offerings, financial highlights, recent news, and analyst insights. The information presented covers market data, financial metrics, and a brief company profile.

Omnicell to release Q3FY26 results on October 29, 2026

https://scanx.trade/stock-market-news/companies/omnicell-release-q3fy26-results-october-29-2026/53046480
Omnicell Inc. will release its financial results for the third quarter of fiscal year 2026 before market open on Thursday, October 29, 2026. The company will host a conference call and webcast at 8:30 am ET on the same day to discuss the results. Dial-in details and webcast access information have been provided for interested parties.

Press Release: Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026

https://www.moomoo.com/news/post/1000784840/press-release-omnicell-to-release-third-quarter-2026-financial-results
Omnicell (Nasdaq: OMCL) will release its third-quarter 2026 financial results on Thursday, October 29, 2026. The company will also host a conference call and webcast on the same day to discuss these results. Interested parties can access the webcast live or via replay on Omnicell's investor relations website.

Is Omnicell (OMCL) Undervalued As Weak EBITDA Guidance Clouds Its Earnings Beat?

https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/is-omnicell-omcl-undervalued-as-weak-ebitda-guidance-clouds/amp
Omnicell (OMCL) slightly exceeded revenue expectations but provided a weak EBITDA outlook, causing investor focus to shift to cost pressures and future profitability. Despite recent short-term gains, the stock has declined significantly over longer periods, yet it trades at a steep discount to analyst targets and intrinsic value estimates. The article explores whether this reflects disciplined risk pricing or an overly harsh penalty, while also noting the company's high P/E ratio compared to its industry.

Is Omnicell (OMCL) Undervalued As Weak EBITDA Guidance Clouds Its Earnings Beat?

https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/is-omnicell-omcl-undervalued-as-weak-ebitda-guidance-clouds
Omnicell (OMCL) recently beat revenue expectations but issued weak EBITDA guidance, shifting investor focus to cost pressures. Despite a 43% undervaluation narrative and short-term stock momentum, its P/E ratio of 41.1x is significantly higher than the industry average, suggesting potential risk if sentiment cools. The company's transition to SaaS-based revenues via its OmniSphere platform is expected to improve margins, though tariff costs and hospital budget pressures remain potential challenges.
Advertisement

Does Omnicell’s Revenue Beat and Weak EBITDA Guidance Change The Bull Case For OMCL?

https://finance.yahoo.com/markets/stocks/articles/does-omnicell-revenue-beat-weak-200955551.html
Omnicell (OMCL) recently reported a 7.4% year-on-year increase in quarterly revenue, slightly exceeding analysts' expectations, but issued weaker-than-forecast EBITDA guidance for the next quarter. This mixed performance highlights a tension between sales momentum and margin pressure, challenging the investment narrative that focuses on the company's shift to profitable, recurring revenue from medication automation and cloud software. Investors should consider how rising costs and pricing pressures could impact future profitability despite strategic integrations like TraceLink with Omnicell Central Pharmacy Manager.

1 Healthcare Stock with Exciting Potential and 2 We Find Risky

https://stockstory.org/us/stocks/nasdaq/omcl/news/buy-or-sell/1-healthcare-stock-with-exciting-potential-and-2-we-find-risky
This article evaluates three healthcare stocks, identifying one with potential and two as risky. It suggests Cardinal Health (CAH) as a stock to watch due to its scale and share buybacks, while advising caution with Omnicell (OMCL) and Lantheus (LNTH) due to slow growth, declining earnings, or rising costs.

Healthcare Technology for Providers Stocks Q2 Recap: Benchmarking Omnicell (NASDAQ:OMCL)

https://www.tradingview.com/news/stockstory:613bc130c094b:0-healthcare-technology-for-providers-stocks-q2-recap-benchmarking-omnicell-nasdaq-omcl/
This article reviews the Q2 performance of several healthcare technology for providers stocks, focusing on Omnicell (OMCL). While the sector as a whole reported strong Q2 revenues, share prices have collectively declined post-earnings. Omnicell experienced a mixed quarter with revenue beat but weak EBITDA guidance, leading to an 18.9% stock decline.

Healthcare Technology for Providers Stocks Q2 Recap: Benchmarking Omnicell (NASDAQ:OMCL)

https://stockstory.org/us/stocks/nasdaq/omcl/news/earnings/healthcare-technology-for-providers-stocks-q2-recap-benchmarking-omnicell-nasdaqomcl
This article reviews the Q2 performance of healthcare technology for providers stocks, focusing on Omnicell (NASDAQ:OMCL). While Omnicell reported a revenue beat, its guidance was weak, leading to a significant stock drop. In contrast, Evolent Health (NYSE:EVH) posted strong results, outperforming expectations and seeing its stock rise.

Trading Systems Reacting to (OMCL) Volatility

https://news.stocktradersdaily.com/news_release/98/Trading_Systems_Reacting_to_OMCL_Volatility_100326054401_1791020641.html
Omnicell Inc. (NASDAQ: OMCL) is exhibiting a neutral sentiment across all time horizons, indicating a wait-and-see approach. The AI models have generated three distinct trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy. The analysis also highlights an exceptional 76.9:1 risk-reward setup, targeting a 21.7% gain against a 0.3% risk.
Advertisement

Cost of goods sold of Omnicell, Inc. – HAN:OC9

https://www.tradingview.com/symbols/HAN-OC9/financials-income-statement/cost-of-goods/
This article displays the "Cost of goods sold" for Omnicell, Inc. (HAN:OC9) on the TradingView platform. It provides a quick financial snapshot, indicating the market is currently closed with no trades. The data is provided by ICE Data Services and FactSet.

Omnicell, Inc. Bonds — Corporate Bond Rates

https://www.tradingview.com/symbols/HAN-OC9/bonds/
This article provides a list of corporate bonds for Omnicell, Inc., sorted by yield to worst, aimed at investors looking for stability. It details one specific bond (OMCL6251486) with a 1.0% coupon rate maturing on December 1, 2029, and its outstanding amount and face value. The information is presented through TradingView, emphasizing the reliability of corporate bonds in volatile markets.

Omnicell stock reports 7.40 percent revenue growth in Q2 2026

https://www.ad-hoc-news.de/boerse/news/nebenwerte/omnicell-stock-reports-7-40-percent-revenue-growth-in-q2-2026/70200319
Omnicell (OMCL) reported a 7.40 percent year-over-year revenue growth in Q2 2026, reaching USD 312.20 million, which exceeded analyst estimates. The company's EPS was USD 0.94, significantly higher than the consensus of USD 0.47. Despite strong Q2 results, the stock is trading below its yearly high, and Q3 2026 EPS guidance is set lower, highlighting the importance of execution in its medication-cabinet refresh cycle.

Omnicell stock trades 39.95 percent below its yearly high

https://www.ad-hoc-news.de/boerse/news/nebenwerte/omnicell-stock-trades-39-95-percent-below-its-yearly-high/70182392
Omnicell stock is trading significantly below its 52-week high despite strong Q2 2026 financial results, including a 7.4% revenue increase and an EPS beat. The company has a fiscal 2026 consensus EPS estimate of USD 2.15, with analysts revising forecasts upwards. Omnicell is pursuing a product refresh, but its stock price remains closer to its yearly low.

Why Omnicell (OMCL) Shares Moved And What Investors Are Watching

https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/why-omnicell-omcl-shares-moved-and-what-investors-are-watchi
Omnicell (OMCL) shares have seen recent movement, closing at $33.17, following a period of mixed returns. While recent trading shows a small rebound, the stock has declined over the last 30 days and year-to-date. The article highlights that Omnicell is viewed by many as 46% undervalued with a fair value of $61.29, driven by its OmniSphere platform and transition to SaaS revenues, but also cautions about risks like tariff costs and hospital budget tightening.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement